Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis

Area of Science:

• Nanomedicine
• Biotechnology
• Oncology

Background:

• Cancer theranosis integrates diagnosis and therapy for personalized cancer treatment.
• Understanding nanoparticle behavior in vivo is crucial for effective drug delivery.
• Targeting specific receptors on cancer cells enhances therapeutic outcomes.

Purpose of the Study:

• To develop a novel lipid micellar nanoparticle system for cancer theranosis.
• To co-load paclitaxel (PTX) and quantum dots (QDs) into targeted nanoparticles.
• To evaluate the in vivo tumor targeting, bio-distribution, and therapeutic efficacy of the theranostic nanoparticles.

Main Methods:

• Lipid micellar nanoparticles were engineered to co-load PTX and QDs.
• Antibodies or aptamers against EGFR were conjugated to the micelle surface for tumor targeting.
• Systemic administration in mice bearing EGFR-positive tumors followed by in vivo imaging and bio-distribution studies.
• Therapeutic efficacy was assessed by monitoring tumor growth inhibition.

Main Results:

• Targeted nanoparticles (immuno-QDMs and aptamo-QDMs) exhibited prolonged blood circulation (≥8 h).
• Significant accumulation of targeted nanoparticles was observed in tumor tissues.
• Targeted nanoparticles demonstrated enhanced inhibition of LS174T tumor growth compared to non-targeted nanoparticles.

Conclusions:

• Anti-EGFR targeted theranostic nanoparticles show promise for effective cancer treatment.
• The developed system enables simultaneous imaging and drug delivery for personalized cancer therapy.
• This approach holds potential for clinical application in treating EGFR-positive tumors.